{"id":"https://openalex.org/W2908362803","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps3116","title":"A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.","display_name":"A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W2908362803","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps3116","mag":"2908362803"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.tps3116","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps3116","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps3116","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guillermo Garcia-Manero","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073761054","display_name":"Giovanni Martinelli","orcid":"https://orcid.org/0000-0002-1025-4210","observed_orcids":["https://orcid.org/0000-0002-1025-4210"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giovanni Martinelli","raw_affiliation_strings":["DIMES, Institute of Hematology, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DIMES, Institute of Hematology, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040303721","display_name":"Joshua F. Zeidner","orcid":"https://orcid.org/0000-0002-9014-1514","observed_orcids":["https://orcid.org/0000-0002-9014-1514"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210150714","display_name":"Johns Hopkins Hospital","ror":"https://ror.org/05cb1k848","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210150714"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua F. Zeidner","raw_affiliation_strings":["The Johns Hopkins Hospital and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Johns Hopkins Hospital and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210150714","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052641327","display_name":"David Avigan","orcid":"https://orcid.org/0000-0003-4624-6017","observed_orcids":["https://orcid.org/0000-0003-4624-6017"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Avigan","raw_affiliation_strings":["Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Carl Anderson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032462496","display_name":"Vincent Ribrag","orcid":"https://orcid.org/0000-0002-5221-353X","observed_orcids":["https://orcid.org/0000-0002-5221-353X"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Ribrag","raw_affiliation_strings":["Institut Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001102192","display_name":"Craig H. Moskowitz","orcid":"https://orcid.org/0000-0002-9189-3152","observed_orcids":["https://orcid.org/0000-0002-9189-3152"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Craig Moskowitz","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091882595","display_name":"Pier Luigi Zinzani","orcid":"https://orcid.org/0000-0002-2112-2651","observed_orcids":["https://orcid.org/0000-0002-2112-2651"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Pier Luigi Zinzani","raw_affiliation_strings":["University of Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086085318","display_name":"Dianna Wu","orcid":"https://orcid.org/0000-0002-4814-3620","observed_orcids":["https://orcid.org/0000-0002-4814-3620"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dianna Wu","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062557677","display_name":"Kenneth Emancipator","orcid":"https://orcid.org/0000-0002-6629-4430","observed_orcids":["https://orcid.org/0000-0002-6629-4430"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Emancipator","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084659842","display_name":"Marisa P Dolled-Filhart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marisa Dolled-Filhart","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048903763","display_name":"Christine K. Gause","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Gause","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065954033","display_name":"Holly M. Brown","orcid":"https://orcid.org/0000-0001-5841-188X","observed_orcids":["https://orcid.org/0000-0001-5841-188X"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly Brown","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086945063","display_name":"Ryan D. Geschwindt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan D. Geschwindt","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103393223","display_name":"Robert Iannone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Iannone","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112451928","display_name":"Shelonitda Rose","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shelonitda Rose","raw_affiliation_strings":["Merck & Co., Inc., Whitehouse Station, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112191399","display_name":"Phillippe Armand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Phillippe Armand","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"TPS3116","last_page":"TPS3116"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.017400000244379044,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/anti-pd-1-monoclonal-antibody","display_name":"anti-PD-1 monoclonal antibody","score":0.9210000038146973},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.9639999866485596},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9850000143051147},{"id":"https://openalex.org/keywords/relapsed-refractory-hodgkin-lymphoma","display_name":"relapsed/refractory Hodgkin lymphoma","score":0.9570000171661377},{"id":"https://openalex.org/keywords/primary-mediastinal-large-b-cell-lymphoma","display_name":"primary mediastinal B-cell lymphoma","score":0.9679999947547913},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9129999876022339},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6209999918937683},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6759999990463257},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.5720000267028809},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.7720000147819519},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.937206506729126},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6719180941581726},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6718325018882751},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5930747389793396},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5404253005981445},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5024905204772949},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.45900675654411316},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.44487494230270386},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4349293112754822},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4196126461029053},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4050002992153168},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3502132296562195},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.29903843998908997},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.tps3116","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps3116","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps3116","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2595070529","https://openalex.org/W2206022232","https://openalex.org/W2606964316","https://openalex.org/W2011044258","https://openalex.org/W2249078564","https://openalex.org/W2538639548","https://openalex.org/W2598169592","https://openalex.org/W2908271323","https://openalex.org/W2211214375","https://openalex.org/W2988870724"],"abstract_inverted_index":{"TPS3116":[0],"Background:":[1],"Hematologic":[2],"malignancies":[3],"(HMs)":[4],"are":[5,61,127],"responsive":[6],"to":[7,14,36,128,215],"immunotherapy,":[8],"but":[9],"in":[10,70,84,90,202,223,229,235,241],"some":[11,45],"cases":[12],"appear":[13],"usurp":[15],"the":[16,63,177,203,207,210,220],"PD-1":[17,38],"pathway":[18],"for":[19,162,231,237,243],"tumor":[20],"immune":[21,53],"escape.":[22],"MK-3475":[23,50,69,143],"is":[24,76],"a":[25,77,217,224],"potent,":[26],"highly":[27],"selective,":[28],"humanized":[29],"IgG4/kappa":[30],"isotype,":[31],"anti-PD-1":[32],"monoclonal":[33],"antibody":[34],"designed":[35],"block":[37],"interaction":[39],"with":[40,47,72,86,245],"PD-L1":[41,168],"and":[42,55,65,106,132,165,170,176,183],"PD-L2.":[43],"In":[44],"patients":[46,71,85,89],"solid":[48],"tumors,":[49],"enhances":[51],"anti-tumor":[52,184],"activity":[54,67],"has":[56],"demonstrated":[57],"therapeutic":[58],"activity.":[59,185],"We":[60],"testing":[62],"safety":[64,204],"preliminary":[66],"of":[68,140,158,179,251],"HMs.":[73],"Methods:":[74],"This":[75],"multicenter,":[78],"nonrandomized,":[79],"open-label":[80],"phase":[81],"1b":[82],"trial":[83,254],"HMs,":[87],"enrolling":[88],"3":[91],"separate":[92],"cohorts":[93],":":[94],"hypomethylating":[95],"agent":[96],"failure":[97],"myelodysplastic":[98],"syndrome":[99],"(MDS);":[100],"relapsed/refractory":[101],"(R/R)":[102],"Hodgkin":[103],"lymphoma":[104,112,116],"(HL);":[105],"primary":[107,125,208],"mediastinal":[108],"large":[109],"B":[110],"cell":[111],"(MLBCL)/PD-L1":[113],"positive":[114],"non-Hodgkin":[115],"(NHL).":[117],"Approximately":[118],"78":[119],"pts":[120],"will":[121,187,199],"be":[122,188,200],"enrolled.":[123],"The":[124],"objectives":[126,155,173],"determine":[129],"safety,":[130],"tolerability,":[131],"objective":[133],"response":[134],"rate":[135,139,250],"or":[136,151],"complete":[137],"remission":[138],"10":[141],"mg/kg":[142],"dosed":[144],"every":[145],"2":[146],"weeks":[147],"until":[148],"disease":[149],"progression":[150],"excessive":[152],"toxicity.":[153],"Secondary":[154],"include":[156,174],"analysis":[157],"efficacy":[159],"parameters":[160],"(DOR/PFS/OS)":[161],"each":[163],"indication,":[164],"association":[166],"between":[167],"expression":[169],"response.":[171],"Exploratory":[172],"PK":[175],"relationship":[178],"candidate":[180],"efficacy/resistance":[181],"biomarkers":[182],"Response":[186],"evaluated":[189],"using":[190],"standard":[191],"criteria.":[192],"Patients":[193],"receiving":[194],"at":[195],"least":[196],"1":[197],"dose":[198],"included":[201],"analysis.":[205],"For":[206],"endpoint,":[209],"study":[211],"provides":[212],"~80%":[213],"power":[214],"detect":[216],"difference":[218,228,234,240],"under":[219],"null":[221],"hypothesis":[222],"given":[225],"cohort":[226],"(20%":[227],"ORR":[230,242],"MDS;":[232],"20%":[233],"CRR":[236],"HL,":[238],"25%":[239],"MLBCL/NHL)":[244],"one-sided":[246],"type":[247],"I":[248],"error":[249],"5%.":[252],"Clinical":[253],"information:":[255],"NCT01953692.":[256]},"counts_by_year":[{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2019-01-11T00:00:00"}